Susanna Klevebro1, Gunnel Hellgren2, Ingrid Hansen-Pupp3, Dirk Wackernagel4, Boubou Hallberg4, Jan Borg5, Aldina Pivodic6, Lois Smith7, David Ley3, Ann Hellström8. 1. Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden. Electronic address: susanna.klevebro@ki.se. 2. Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; Institute of Bioscience, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden. 3. Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Pediatrics, Lund, Sweden. 4. Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden. 5. Former Premacure AB, Uppsala, Sweden. 6. Statistiska konsultgruppen, Gothenburg, Sweden. 7. Department of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States of America. 8. Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Abstract
OBJECTIVE: Steady state insulin-like growth factor-1 (IGF-1) levels vary significantly during continuous intravenous infusion of recombinant human insulin-like growth factor-1/recombinant human insulin-like growth factor binding protein-3 (rhIGF-1/rhIGFBP-3) in the first weeks of life in extremely preterm infants. We evaluated interleukin-6 (IL-6) and insulin-like growth factor binding protein-1 (IGFBP-1) levels as predictors of low IGF-1 levels. METHODS: Nineteen extremely preterm infants were enrolled in a trial, 9 received rhIGF-1/rhIGFBP-3 and 10 received standard neonatal care. Blood samples were analyzed daily for IGF-1, IL-6 and IGFBP-1 during intervention with rhIGF-1/rhIGFBP-3. RESULTS: Thirty seven percent of IGF-1 values during active treatment were <20 μg/L. Among treated infants, higher levels of IL-6, one and two days before sampled IGF-1, were associated with IGF-1 < 20 μg/L, gestational age adjusted OR 1.30 (95% CI 1.03-1.63), p = .026, and 1.57 (95% CI 1.26-1.97), p < .001 respectively. Higher levels of IGFBP-1 one day before sampled IGF-1 was also associated with IGF-1 < 20 μg/L, gestational age adjusted OR 1.74 (95% CI 1.19-2.53), p = .004. CONCLUSION: In preterm infants receiving continuous infusion of rhIGF-1/rhIGFBP-3, higher levels of IL-6 and IGFBP-1 preceded lower levels of circulating IGF-1. These findings demonstrate a need to further evaluate if inflammation and/or infection suppress serum IGF-1 levels. The trial is registered at ClinicalTrials.gov (NCT01096784).
OBJECTIVE: Steady state insulin-like growth factor-1 (IGF-1) levels vary significantly during continuous intravenous infusion of recombinant humaninsulin-like growth factor-1/recombinant humaninsulin-like growth factor binding protein-3 (rhIGF-1/rhIGFBP-3) in the first weeks of life in extremely preterm infants. We evaluated interleukin-6 (IL-6) and insulin-like growth factor binding protein-1 (IGFBP-1) levels as predictors of low IGF-1 levels. METHODS: Nineteen extremely preterm infants were enrolled in a trial, 9 received rhIGF-1/rhIGFBP-3 and 10 received standard neonatal care. Blood samples were analyzed daily for IGF-1, IL-6 and IGFBP-1 during intervention with rhIGF-1/rhIGFBP-3. RESULTS: Thirty seven percent of IGF-1 values during active treatment were <20 μg/L. Among treated infants, higher levels of IL-6, one and two days before sampled IGF-1, were associated with IGF-1 < 20 μg/L, gestational age adjusted OR 1.30 (95% CI 1.03-1.63), p = .026, and 1.57 (95% CI 1.26-1.97), p < .001 respectively. Higher levels of IGFBP-1 one day before sampled IGF-1 was also associated with IGF-1 < 20 μg/L, gestational age adjusted OR 1.74 (95% CI 1.19-2.53), p = .004. CONCLUSION: In preterm infants receiving continuous infusion of rhIGF-1/rhIGFBP-3, higher levels of IL-6 and IGFBP-1 preceded lower levels of circulating IGF-1. These findings demonstrate a need to further evaluate if inflammation and/or infection suppress serum IGF-1 levels. The trial is registered at ClinicalTrials.gov (NCT01096784).
Authors: Wen Hong Shen; Yuxin Yin; Suzanne R Broussard; Robert H McCusker; Gregory G Freund; Robert Dantzer; Keith W Kelley Journal: J Biol Chem Date: 2003-12-16 Impact factor: 5.157
Authors: Ann Hellström; Eva Engström; Anna-Lena Hård; Kerstin Albertsson-Wikland; Björn Carlsson; Aimon Niklasson; Chatarina Löfqvist; Elisabeth Svensson; Sture Holm; Uwe Ewald; Gerd Holmström; Lois E H Smith Journal: Pediatrics Date: 2003-11 Impact factor: 7.124
Authors: F de Groof; K F M Joosten; J A M J L Janssen; E D de Kleijn; J A Hazelzet; W C J Hop; P Uitterlinden; J van Doorn; A C S Hokken-Koelega Journal: J Clin Endocrinol Metab Date: 2002-07 Impact factor: 5.958
Authors: Alan Leviton; Elizabeth N Allred; Raina N Fichorova; Deborah K VanderVeen; T Michael O'Shea; Karl Kuban; Olaf Dammann Journal: Am J Perinatol Date: 2019-01-27 Impact factor: 1.862
Authors: Ingrid Hansen-Pupp; Holger Hövel; Chatarina Löfqvist; Lena Hellström-Westas; Vineta Fellman; Petra S Hüppi; Ann Hellström; David Ley Journal: Pediatr Res Date: 2013-08-13 Impact factor: 3.756
Authors: David Ley; Boubou Hallberg; Ingrid Hansen-Pupp; Carlo Dani; Luca A Ramenghi; Neil Marlow; Kathryn Beardsall; Faizah Bhatti; David Dunger; Jason D Higginson; Ajit Mahaveer; Olachi J Mezu-Ndubuisi; Peter Reynolds; Carmen Giannantonio; Mirjam van Weissenbruch; Norman Barton; Adina Tocoian; Mohamed Hamdani; Emily Jochim; Alexandra Mangili; Jou-Ku Chung; Mark A Turner; Lois E H Smith; Ann Hellström Journal: J Pediatr Date: 2018-11-22 Impact factor: 4.406
Authors: Ann Hellström; David Ley; Ingrid Hansen-Pupp; Boubou Hallberg; Chatarina Löfqvist; Linda van Marter; Mirjam van Weissenbruch; Luca A Ramenghi; Kathryn Beardsall; David Dunger; Anna-Lena Hård; Lois E H Smith Journal: Acta Paediatr Date: 2016-03-08 Impact factor: 2.299
Authors: Ann Hellstrom; David Ley; Boubou Hallberg; Chatarina Lofqvist; Ingrid Hansen-Pupp; Luca A Ramenghi; Jan Borg; Lois E H Smith; Anna-Lena Hard Journal: Curr Pharm Des Date: 2017 Impact factor: 3.116
Authors: Kristine Holgersen; Martin Bo Rasmussen; Galen Carey; Douglas G Burrin; Thomas Thymann; Per Torp Sangild Journal: Front Pediatr Date: 2022-08-05 Impact factor: 3.569